Ralevic Vera
School of Biomedical Sciences, Queen's Medical Centre, University of Nottingham Medical School, Nottingham NG7 2UH, UK.
Eur J Pharmacol. 2003 Jul 4;472(1-2):1-21. doi: 10.1016/s0014-2999(03)01813-2.
Cannabinoids are cell membrane-derived signalling molecules that are released from nerves, blood cells and endothelial cells, and have diverse biological effects. They act at two distinct types of G-protein-coupled receptors, cannabinoid CB(1) and CB(2) receptors. Cannabinoid CB(1) receptors are highly localised in the central nervous system and are also found in some peripheral tissues, and cannabinoid CB(2) receptors are found outside the central nervous system, in particular in association with immune tissues. Novel actions of cannabinoids at non-CB(1) non-CB(2) cannabinoid-like receptors and vanilloid VR1 receptors have also recently been described. There is growing evidence that, among other roles, cannabinoids can act at prejunctional sites to modulate peripheral autonomic and sensory neurotransmission, and the present article is aimed at providing an overview of this. Inhibitory cannabinoid CB(1) receptors are expressed on the peripheral terminals of autonomic and sensory nerves. The role of cannabinoid receptor ligands in modulation of sensory neurotransmission is complex, as certain of these (anandamide, an "endocannabinoid", and N-arachidonoyl-dopamine, an "endovanilloid") also activate vanilloid VR1 receptors (coexpressed with cannabinoid CB(1) receptors), which excites sensory nerves and causes a release of sensory neurotransmitter. The fact that the activities of anandamide and N-arachidonoyl-dopamine span two distinct receptor families raises important questions about cannabinoid/vanilloid nomenclature, and as both compounds are structurally related to the archetypal vanilloid capsaicin, all three are arguably members of the same family of signalling molecules. Anandamide is released from nerves, but unlike classical neurotransmitters, it is not stored in and released from nerve vesicles, but is released on demand from the nerve cell membrane. In the central nervous system, cannabinoids function as retrograde signalling molecules, inhibiting via presynaptic cannabinoid CB(1) receptors the release of classical transmitter following release from the postsynaptic cell. At the neuroeffector junction, it is more likely that cannabinoids are released from prejunctional sites, as the neuroeffector junction is wide in some peripheral tissues and cannabinoids are rapidly taken up and inactivated. Understanding the actions of cannabinoids as modulators of peripheral neurotransmission is relevant to a variety of biological systems and possibly their disorders.
大麻素是源自细胞膜的信号分子,由神经、血细胞和内皮细胞释放,具有多种生物学效应。它们作用于两种不同类型的G蛋白偶联受体,即大麻素CB(1)受体和CB(2)受体。大麻素CB(1)受体高度定位于中枢神经系统,也存在于一些外周组织中;大麻素CB(2)受体则存在于中枢神经系统之外,尤其与免疫组织相关。最近也有关于大麻素在非CB(1)非CB(2)类大麻素样受体和香草酸VR1受体上的新作用的描述。越来越多的证据表明,除其他作用外,大麻素可作用于突触前位点来调节外周自主神经和感觉神经传递,本文旨在对此进行综述。抑制性大麻素CB(1)受体表达于自主神经和感觉神经的外周终末。大麻素受体配体在调节感觉神经传递中的作用较为复杂,因为其中某些配体(花生四烯乙醇胺,一种“内源性大麻素”,以及N-花生四烯酰多巴胺,一种“内源性香草酸”)也可激活香草酸VR1受体(与大麻素CB(1)受体共表达),从而兴奋感觉神经并导致感觉神经递质释放。花生四烯乙醇胺和N-花生四烯酰多巴胺的活性跨越两个不同受体家族这一事实,引发了关于大麻素/香草酸命名的重要问题,而且由于这两种化合物在结构上均与原型香草酸辣椒素相关,所以这三种化合物都可以说是同一信号分子家族的成员。花生四烯乙醇胺从神经释放,但与经典神经递质不同,它并非储存于神经囊泡中并从中释放,而是根据需要从神经细胞膜释放。在中枢神经系统中,大麻素作为逆行信号分子,通过突触前大麻素CB(1)受体抑制突触后细胞释放经典递质后经典递质的释放。在神经效应器连接处,大麻素更有可能从突触前位点释放,因为在一些外周组织中神经效应器连接处较宽,且大麻素会迅速被摄取并失活。了解大麻素作为外周神经传递调节剂的作用与多种生物系统及其可能的紊乱情况相关。